Functional RsaI/PstI Polymorphism in Cytochrome P450 2E1 Contributes to Bladder Cancer Susceptibility: Evidence from a Meta-analysis

  • Deng, Xiao-Dong (Department of Forensic Medicine, North Sichuan Medical College) ;
  • Gao, Qin (Nanchong Central Hospital) ;
  • Zhang, Bo (Department of Forensic Medicine, North Sichuan Medical College) ;
  • Zhang, Li-Xia (Department of Forensic Medicine, North Sichuan Medical College) ;
  • Zhang, Wei (Department of Forensic Medicine, North Sichuan Medical College) ;
  • Er, Zhe-Er Mu (Department of Forensic Medicine, North Sichuan Medical College) ;
  • Xie, Ying (Department of Forensic Medicine, North Sichuan Medical College) ;
  • Ma, Ying (Department of Neurology, Affiliated Hospital of North Sichuan Medical College) ;
  • Liu, Yun (Department of Forensic Medicine, North Sichuan Medical College)
  • Published : 2014.06.30


Background: Cytochrome P450 2E1 (CYP2E1) might be involved in the development of bladder cancer. However, previous studies of any association between CYP2E1 RsaI/PstI polymorphism and bladder cancer risk have yielded conflicting results. In this study, we performed a more precise estimation of the relationship by a meta-analysis based on the currently available evidence from the literature. Method: To assess the effect of CYP2E1 RsaI/PstI polymorphism on bladder cancer susceptibility, a meta-analysis of 6 available studies with 1,510 cases and 1,560 controls were performed through Feb 2014. Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were used to estimate the strength of association for CYP2E1 RsaI/PstI polymorphism under different genetic models. Results: When available studies were pooled into the meta-analysis, we found that the C1C2 and C2C2 genotypes of CYP2E1 RsaI/PstI polymorphism significantly decreased bladder cancer risk under different genetic models (heterozygote: OR=0.766, 95%CI=0.613-0.957, $P_{OR}$=0.019; homozygote: OR=0.51, 95%CI=0.303-0.858, $P_{OR}$=0.011; dominant: OR=0.733, 95%CI=0.593-0.905, $P_{OR}$=0.004; recessive: OR=0.565, 95%CI=0.337-0.947, $P_{OR}$=0.030). Subgroup analysis indicated that C2C2 genotype was significantly associated with decreased bladder cancer risk under the homozygote genetic model in Caucasians. There was no evidence of heterogeneity or publication bias. Conclusions: The current meta-analysis suggested that the CYP2E1 RsaI/PstI polymorphism might be associated with bladder cancer susceptibility, especially in Caucasians. Further studies are needed to validate the above conclusion.


  1. Zabost A, Zwolska Z and Augustynowicz-Kopec E (2013). [The biological role of prokaryotic and eukaryotic N-acetyltransferase]. Pneumonol Alergol Pol, 81, 137-44.
  2. Yamazaki H, Inui Y, Yun CH, Guengerich FP and Shimada T (1992). Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13, 1789-94.
  3. Yu MW, Gladek-Yarborough A, Chiamprasert S, et al (1995). Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology, 109, 1266-73.
  4. Yue J, Peng R, Chen J, Liu Y and Dong G (2009). Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats. Pharmacol Res, 59, 112-9.
  5. Zgheib NK, Mitri Z, Geryess E and Noutsi P (2010). Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a Lebanese population: frequency distribution and association with morbid diseases. Genet Test Mol Biomarkers, 14, 393-7.
  6. Zhang X, Lin J, Wu X, et al (2012). Association between GSTM1 copy number, promoter variants and susceptibility to urinary bladder cancer. Int J Mol Epidemiol Genet, 3, 228-36.
  7. Stephens EA, Taylor JA, Kaplan N, et al (1994). Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics, 4, 185-92.
  8. Shao J, Gu M, Zhang Z, et al (2008). Genetic variants of the cytochrome P450 and glutathione S-transferase associated with risk of bladder cancer in a south-eastern Chinese population. Int J Urol, 15, 216-21.
  9. Sheweita SA, Abu El-Maati MR, El-Shahat FG and Bazeed MA (2001). Changes in the expression of cytochrome P450 2E1 and the activity of carcinogen-metabolizing enzymes in Schistosoma haematobium-infected human bladder tissues. Toxicology, 162, 43-52.
  10. Steck SE and Hebert JR (2009). GST polymorphism and excretion of heterocyclic aromatic amine and isothiocyanate metabolites after Brassica consumption. Environ Mol Mutagen, 50, 238-46.
  11. Strope SA and Montie JE (2008). The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol, 180, 31-7; discussion 37.
  12. Taioli E and Raimondi S (2005). Genetic susceptibility to bladder cancer. Lancet, 366, 610-2.
  13. Tian Z, Li YL, Zhao L and Zhang CL (2012). CYP2E1 RsaI/PstI polymorphism and liver cancer risk among east Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev, 13, 4915-21.
  14. Uematsu F, Kikuchi H, Ohmachi T, et al (1991). Two common RFLPs of the human CYP2E gene. Nucleic Acids Res, 19, p. 2803.
  15. Wang Y, Yang H, Li L, et al (2009). Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer, 46, 758-64.
  16. Mantel N and Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  17. Lin DX, Tang YM, Peng Q, et al (1998). Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev, 7, 1013-8.
  18. London SJ, Daly AK, Cooper J, et al (1996). Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics, 6, 151-8.
  19. Lucas D, Menez C, Girre C, et al (1995). Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics, 5, 298-304.
  20. Mittal RD, Srivastava DS, A M and B M (2005). Genetic polymorphism of drug metabolizing enzymes (CYP2E1, GSTP1) and susceptibility to bladder cancer in North India. Asian Pac J Cancer Prev, 6, 6-9.
  21. Munafo MR and Flint J (2004). Meta-analysis of genetic association studies. Trends Genet, 20, 439-44.
  22. Pandith AA, Lateef A, Shahnawaz S, et al (2013). GSTP1 gene Ile105Val polymorphism causes an elevated risk for bladder carcinogenesis in smokers. Asian Pac J Cancer Prev, 14, 6375-8.
  23. Parkin DM (2008). The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl, 12-20.
  24. Persson I, Johansson I, Bergling H, et al (1993). Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett, 319, 207-11.
  25. Shahriary GM, Galehdari H, Jalali A, et al (2012). CYP2E1*5B, CYP2E1*6, CYP2E1*7B, CYP2E1*2, and CYP2E1*3 allele frequencies in iranian populations. Asian Pac J Cancer Prev, 13, 6505-10.
  26. Johansson I, Lindros KO, Eriksson H and Ingelman-Sundberg M (1990). Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. Biochem Biophys Res Commun, 173, 331-8.
  27. Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  28. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A and Vainio H (1993). The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis, 14, 85-8.
  29. Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-74.
  30. Kim RB and O'Shea D (1995). Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther, 57, 645-55.
  31. Kim RB, Yamazaki H, Chiba K, et al (1996). In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther, 279, 4-11.
  32. Ladero JM, Agundez JA, Rodriguez-Lescure A, Diaz-Rubio M and Benitez J (1996). RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Gut, 39, 330-3.
  33. Lakkakula S, Maram R, Munirajan AK, et al (2013). Functional PstI/RsaI polymorphisms in the CYP2E1 gene among south Indian populations. Asian Pac J Cancer Prev, 14, 179-82.
  34. Le Marchand L, Sivaraman L, Pierce L, et al (1998). Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res, 58, 4858-63.
  35. Leng WD, Zeng XT, Chen YJ, et al (2012). Cytochrome P450 2E1 RsaI/PstI polymorphism and risk of esophageal cancer: A meta-analysis of 17 case-control studies. Exp Ther Med, 4, 938-948.
  36. Choi JY, Lee KM, Cho SH, et al (2003). CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics, 13, 349-55.
  37. Brockmoller J, Cascorbi I, Kerb R and Roots I (1996). Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res, 56, 3915-25.
  38. Cantor KP, Villanueva CM, Silverman DT, et al (2010). Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. Environ Health Perspect, 118, 1545-50.
  39. Carriere V, Berthou F, Baird S, et al (1996). Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics, 6, 203-11.
  40. Clapp RW, Jacobs MM and Loechler EL (2008). Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health, 23, 1-37.
  41. Danko IM and Chaschin NA (2005). Association of CYP2E1 gene polymorphism with predisposition to cancer development. Exp Oncol, 27, 248-56.
  42. DerSimonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  43. Gonzalez FJ (2005). Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res, 569, 101-10.
  44. Guengerich FP, Kim DH and Iwasaki M (1991). Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol, 4, 168-79.
  45. Hayashi S, Watanabe J and Kawajiri K (1991). Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem, 110, 559-65.
  46. Basma HA, Kobeissi LH, Jabbour ME, Moussa MA and Dhaini HR (2013). CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population. Int J Mol Epidemiol Genet, 4, 207-17.

Cited by

  1. Significant Genotype Difference in the CYP2E1 PstI Polymorphism of Indigenous Groups in Sabah, Malaysia with Asian and Non-Asian Populations vol.15, pp.17, 2014,
  2. 2,4-Dimethylaniline generates phosphorylated histone H2AX in human urothelial and hepatic cells through reactive oxygen species produced by cytochrome P450 2E1 vol.92, pp.10, 2018,